Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > CEO said, "we are undervalued". Okay, so how what is an
View:
Post by subaru1i on Apr 19, 2024 9:50am

CEO said, "we are undervalued". Okay, so how what is an

approximate 'fair value' for LABS?   Do we have any historical data to help us fairly value LABS?   Not exactly but we do have a few data points at least that we know we are waiting on.   Here's the data points I have if I had to value LABS fairly or at least in the same ball park.

1) FDA approval pending on the ANDA 
2) FDA approval pending on the 505(b)2

So those are at least 2 new drugs for LABS and we know one of them is for a generic Epidiolex.  And the other new drug we don't know yet.   We also have a third data point.  

3) JAZZ acquired GW Pharmaceuticals for $7.2 billion


That's about all I can think of as far as data points to help guide me in giving me some sort of direction of what fair market value would be for LABS when the 2 FDA approvals are granted. 

We the ANDA and 505(b)2 approved and at $10 per share for LABS, we only have a market cap valuation of around $4.1 billion.   That still looks like a bargain compared to GW.  

......just so the newer and younger longs understand what you own.
Comment by okgonow on Apr 19, 2024 9:58am
LOL right after he said we are undervalued he mentioned that we should be trading around the $.15 mark so much for $10
Comment by QContinuum1 on Apr 19, 2024 11:08am
Fair value for LABS is what the market says it is.  Debating fairness is nonsense and LABS is not GW. Maybe one day if everything breaks for LABS properly we can get a proper valuation but I suspect that there are many that are still nervous about the 400mil shares out and a RS.
Comment by Starkicker on Apr 19, 2024 11:56am
100% right QC1. Share buyback is a necessity at this point.
Comment by okgonow on Apr 19, 2024 12:34pm
how bout the officers of the company starting to make some public market buys to show that they really mean what they say !!!!!!!!!!!!!!!!!! so far they just issue themselves warrants  time to step up!!!!
Comment by QContinuum1 on Apr 19, 2024 12:36pm
As I've said before, nothing would tell the market that LABS is a player more than taking a part of the current cash reserve and doing a buyback at near all time lows. You wanna prove that management believes profitability is a whisker away, do a buyback because we'll have money coming in anyhow. You wanna prove that management is aware of the massive float and won't screw existing ...more  
Comment by okgonow on Apr 19, 2024 1:36pm
that tells me they have a problem putting their own money where their mouths are.... if they did that it fullfills all your points as well as the shares held by them would essentially be off the market as well a no brainer if they know oodles of money ids coming in ans SP will go up... using company money to do a share buyback in essence uses shareholders money to achieve this, I am not opposed ...more  
Comment by QContinuum1 on Apr 19, 2024 2:52pm
They don't need to buy more bolt-on pennies on the dollar outfits to start executing on their business plan.  Using the money they have now to do another M&A exercise is just kicking the can down the road and does nothing in the near term for shareholders.  And while it may not mean dilution (although I can see how some shares would be offered to managers etc), the current ...more  
Comment by okgonow on Apr 19, 2024 3:18pm
lol ---whats EGO got to do with making a smart M&A -- i have a feeling you fealt that way when they bought VIVO....... and as you can see that would have been the absolute worst position as they have now prooven what a excellent aquisition VIVO was, once they were fully absorbed. any M&A would have to be done with results like VIVO merger in mind, management hit that nail 100% on the head ...more  
Comment by QContinuum1 on Apr 19, 2024 3:24pm
Ego has everything to do with M&A when M&A isn't needed and persons driving the M&A are looking to empire build rather than execute.
Comment by okgonow on Apr 19, 2024 3:27pm
so tell me how do you feel about the VIVO M&A  was that empire build or  smart aquisition that helped execute and get us to where we are quicker and cheaper?
Comment by okgonow on Apr 20, 2024 7:15am
  you still haven't answered my question Q..... how do you f this l about the Vivo acquisition????? Everyone is entitled to their opinion but: I think the only EGO that's getting in the way of what would or wouldn't make sense is yours and your need to be right. not that we have any say in the matter I will judge MDJ decisions on how to spend the cash on results they ...more  
Comment by QContinuum1 on Apr 20, 2024 12:00pm
Not sure what question you're asking since it doesn't make sense. But yes, everyone is entitled to their opinion and no, spending more money when the product set is nice and flush is not what LABS needs to do. If you endorse LABS blowing throw their limited cash reserve on pity projects because there might be synergies then I hope you enjoy further dilution and a RS because that what' ...more  
Comment by corvette67 on Apr 22, 2024 4:05pm
Yes, it is a real winner! .075 for about 2 years. GLTA
Comment by subaru1i on Apr 22, 2024 4:57pm
Then be a 'big boy' and sell ALL your shares instead of sticking around here with saracastic comments.  Have a nice day VW 'bug'. 
Comment by okgonow on Apr 22, 2024 5:18pm
hey corvette67 dont worry bout Sub....1i he talks to imaginary alien girlfriends what you said is absolutely correct and frustrating, there is nothing wrong with venting once in a while! Q1 will give us good indication where SP will head in the future not to much longer to wait..hang in there.
Comment by corvette67 on Apr 23, 2024 12:27pm
Thks OCk but i do intend to hold up to Dec since i don't need any more losses. P.S. Sub has been on ignore forever. GLTA
Comment by QContinuum1 on Apr 23, 2024 1:18pm
No reason to sell LABS yet, too many irons in the fire and potential for uptick. That said, these irons need to materialize into concrete results this FY as there aren't any more excuses for kicking the can down the road.  If by end of calendar year, results and SP aren't materially higher, then we've been lied to and/or the LABS leadership team is lazy and/or they backed the ...more  
Comment by okgonow on Apr 19, 2024 3:53pm
and i just re-read your post..... how do you know or assume that a M&A isnt needed???? do you have information that showes the company cant be improved in any way by a M&A at this point? Please share if you do !!! I never insinuated or said that an M&A should be done now unless there is good reason for it and that it will help get us to where we all want MPL to go. what i said is ...more  
Comment by QContinuum1 on Apr 19, 2024 6:39pm
I know that M&A isn't needed since if any company 'needs' M&A to survive and thrive then the company is not healthy. I also know M&A is not needed as the company themselves have indicated time and again that they have right sized the SKUs and have strong partnerships in important jurisdictions in the world, partnerships that presumably would be able to leverage a product ...more  
Comment by okgonow on Apr 20, 2024 6:54am
"if any company 'needs' M&A to survive and thrive then the company is not healthy" again your jumping to all kinds of weird concussions, who said anything about MPL barely surviving and that's why they should or shouldn't do an M&A. also do you know how many companies do M&A's because they see value by buying another company and t Here are a few ...more  
Comment by QContinuum1 on Apr 20, 2024 11:56am
It's cute that somehow you think Disney buying Marvel is the same thing as LABS buying anyone. And incidentally, none of those entities needed to merge to survive or thrive, pretty sure they were all doing well enough on their own.  Raytheon was right on the knife edge of insolvency, lol. But go ahead and think that LABS buying revenue with limited money is the same as Heinz buying ...more  
Comment by mdjbrown on Apr 19, 2024 10:43pm
Dont forget okgonow, the settlement with Tilray included $1 million in product which will help. Non-cash elements also included in the Settlement Agreement are ongoing product considerations: § $1,000,000 in Tilray products (including but not restricted to high-quality flower and extractable biomass). § $500,000 four-year supply agreement to provide Tilray ...more  
Comment by okgonow on Apr 20, 2024 7:05am
  md... how far will a million $ in flower take you they said they have orders for drobinol of 1.5 mill in first Q alone that's just one of their products at let's say a 50% profit margin ( just to make the math easy also I know there are other manufacturing costs involved so this is the 2 minute math)you would need $500k to $750k of raw product to produce the order. your chewing ...more  
Comment by mdjbrown on Apr 20, 2024 10:30am
agree okgonow that they will need a lot of flower as international orders increase, but didnt they also pick up an additional growing facility with the Vivo takeover. If I am not mistaken they now have 3 large grow ops. I dont know what the costs from flower to a finished Dronbinol product is, but Tilray also produces Dronbinol so it could have been a direct $ million dollar product swap to ...more  
Comment by subaru1i on Apr 20, 2024 11:44am
VIVO provided state of the art grow operations, you are correct.   Did Tilray see the legislative changes writing on the wall w.r.t. to Tilray's dronabinol production, ie, not having the same pharmaceutical certifications as LABS and the agreement with LABS was to sustains Tilray's presence in the German market place?....we think that is the case.   The agreement is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities